Tsukamoto K, Chida K, Hayakawa H, Sato A, Nakajima Y, Doi O, Yamaguchi T, Taguchi Y
Department of Internal Medicine, Hamamatsu University School of Medicine, Japan.
Nihon Kyobu Shikkan Gakkai Zasshi. 1997 Jul;35(7):746-54.
Some patients with chronic idiopathic interstitial pneumonia (IIP) experience acute exacerbations (AE). Because the precise mechanisms of AE in patients with IIP remain unclear, the treatment for AE is not established and the efficacy of steroids is controversial. Consequently, it is difficult to predict outcomes in patients with AE of IIP. We therefore studied the relationship between clinical findings, efficacy of treatment, and clinical outcome in patients with AE of IIP. Thirty-two patients were enrolled, and were divided into two groups: 10 who were alive more than one year after the onset of the AE survivors, 8 men and 2 women, and 22 who died within one year of the AE (non-survivors, 17 men and 5 women). Survivors were significantly younger than non-survivors (59.7 +/- 9.9 vs 67.5 +/- 8.2 years, respectively, p < 0.05). The values of PaCO2 measured before the AE were higher in survivors than in non-survivors (43.0 +/- 3.7 vs 38.4 +/- 4.0 torr, respectively, p < 0.05). At the onset of the AE the levels of C-reactive protein in serum were higher in survivors than in non-survivors (13.9 +/- 7.9 vs 7.3 +/- 5.8 mg/dl, respectively, p < 0.05). Chest X-ray films showed progression of ground-glass shadows in both groups when the AE occurred; the radiographic findings did not differ markedly between groups. Of the 22 non-survivors, 7 had received medication before the AE; none of the survivors had received medication before the AE. At the time of the AE all patients were treated with steroid pulse therapy, and the dose of methylprednisolone used, did not differ significantly between groups. These data suggest that three factors are closely related to responsiveness to steroid therapy and to clinical outcomes after AE in patients with IIP: 1) age at the onset on IIP, 2) respiratory status before the AE, and 3) disease activity as reflected by inflammatory reactions.
一些慢性特发性间质性肺炎(IIP)患者会经历急性加重(AE)。由于IIP患者AE的确切机制仍不清楚,AE的治疗方法尚未确立,且类固醇的疗效存在争议。因此,很难预测IIP患者AE的预后。我们因此研究了IIP患者AE的临床特征、治疗效果与临床结局之间的关系。共纳入32例患者,分为两组:10例在AE发作后存活超过一年的患者(存活者,8例男性和2例女性),以及22例在AE发作后一年内死亡的患者(非存活者,17例男性和5例女性)。存活者的年龄显著低于非存活者(分别为59.7±9.9岁和67.5±8.2岁,p<0.05)。AE发作前测量的PaCO2值,存活者高于非存活者(分别为43.0±3.7和38.4±4.0托,p<0.05)。AE发作时,存活者血清中的C反应蛋白水平高于非存活者(分别为13.9±7.9和7.3±5.8mg/dl,p<0.05)。AE发作时,两组的胸部X光片均显示磨玻璃影进展;两组间的影像学表现无明显差异。22例非存活者中,7例在AE发作前接受过药物治疗;存活者在AE发作前均未接受过药物治疗。AE发作时,所有患者均接受了类固醇脉冲治疗,两组使用的甲泼尼龙剂量无显著差异。这些数据表明,有三个因素与IIP患者AE后对类固醇治疗的反应性及临床结局密切相关:1)IIP发作时的年龄,2)AE发作前的呼吸状态,以及3)炎症反应所反映的疾病活动度。